Protocol Ledger

NCT04164901 · Phase III · ACTIVE NOT RECRUITING

Study of Vorasidenib (AG-881) in Participants With Residual or Recurrent Grade 2 Glioma With an IDH1 or IDH2 Mutation (INDIGO)

Interventional Phase III clinical trial protocol NCT04164901 sponsored by Institut de Recherches Internationales Servier in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2020-01-05 Enrollment: 331 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT04164901
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)331 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT04164901
Protocol FieldVerified Registry Value
NCT IdentifierNCT04164901
Consolidated Lead SponsorInstitut de Recherches Internationales Servier
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase III
Overall Recruitment StatusACTIVE NOT RECRUITING
Registered Enrollment331 participants (ACTUAL)
Registered Start Date2020-01-05
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI